Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 1/2017

01-01-2017 | Original Article

The roles of 18F-FDG-PET/CT and US-guided FNAC in assessment of axillary nodal metastases in breast cancer patients

Authors: Yasuharu Nakano, Masakuni Noguchi, Miki Yokoi-Noguchi, Yukako Ohno, Emi Morioka, Takeo Kosaka, Tomoko Takahashi, Hiroshi Minato

Published in: Breast Cancer | Issue 1/2017

Login to get access

Abstract

Background

There is a need for less invasive techniques for preoperative identification of axillary lymph node (ALN) metastases.

Method

Patients underwent ultrasonography (US) and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT), and then US-guided fine needle aspiration cytology (FNAC) and/or sentinel lymph node (SLN) biopsy were performed based on the US findings of the ALNs. Subsequently, patients with positive FNAC as well as those with positive SLN underwent axillary lymph node dissection (ALND). Postoperatively, removed SLNs and ALNs were examined histologically.

Results

Fifty (85 %) of 59 patients with positive 18F-FDG uptake in the axilla had axillary metastases, but 18F-FDG uptake results were false-positive in 9 (15 %) cases. On the other hand, 29 patients with positive FNAC underwent ALND without the need for SLN biopsy, while the remaining 20 patients with negative FNAC as well as 249 patients with negative US findings underwent SLN biopsy. Subsequently, 68 patients with positive SLN underwent ALND.

Conclusions

Positive FDG uptake in the axilla does not always indicate axillary metastasis. US-guided FNAC is useful to avoid unnecessary ALND in patients with positive 18F-FDG uptake. However, SLN biopsy is needed in patients with negative US findings of the ALNs and those with negative FNAC.
Literature
1.
Noguchi M, Morioka E, Ohno Y, Noguchi M, Nakano Y, Kosaka T. The changing role of axillary lymph node dissection for breast cancer. Breast Cancer. 2013;20:41–6.CrossRefPubMed
2.
3.
Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006;354:496–507.CrossRefPubMed
4.
Tatsumi M, Cohade C, Mourtzikos KA, Fishman EK, Wahl RL. Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging. 2006;33:254–62.CrossRefPubMed
5.
Cooper KL, Harna S, Meng Y, Ward SE, Fitzgerald O, Papaioannou D, et al. Positron emission tomography (PET) for assessment of axillary lymph node status in early breast cancer: a systemic review and meta-analysis. Eur J Surg Oncol. 2011;37:187–98.CrossRefPubMed
6.
Bernsdorf M, Berthelsen AK, Wielenga VT, Kroman N, Teilum D, Binderup T, et al. Preoperative PET/CT in early–stage breast cancer. Ann Oncol. 2012;23:2277–82.CrossRefPubMed
7.
Deurloo EE, Tanis PJ, Gilhuijs KGA, Muller SH, Kroger R, Peterse JL, et al. Reduction in the number of sentinel lymph node procedures by preoperative ultrasonography of the axilla in the breast cancer. Eur J Cancer. 2003;39:1068–73.CrossRefPubMed
8.
Sapino A, Cassoni P, Zanon E, Fraire F, Croce S, Coluccia C, et al. Ultrasonographically-guided fine-needle aspiration of axillary lymph nodes: role in breast cancer management. Br J Cancer. 2003;88:702–6.CrossRefPubMedPubMedCentral
9.
Bonnema J, van Geel AN, van Ooijen B, Mali SP, Tijam SL, Henzen-Logmans SC, et al. Ultrasound-guided aspiration biopsy for detection of nonpalpable axillary node metastases in breast cancer patients: new diagnostic method. World J Surg. 1997;21:270–4.CrossRefPubMed
10.
de Kanter AY, van Eijck CHJ, van Geel AN, Kruijt RH, Henzen RH, Paul MA, et al. Multicentre study of ultrasonographically guided axillary node biopsy in patients with breast cancer. Br J Surg. 1999;86:1459–62.CrossRefPubMed
11.
Noguchi M, Inokuchi M, Zen Y. Complement of peritumoral and subareolar injection in breast cancer sentinel lymph node biopsy. J Surg Oncol. 2009;100:100–5.CrossRefPubMed
12.
Noguchi M, Inokuchi M. “Moving window” operation for breast-conserving surgery. Breast Cancer. 2010;17:56–60.CrossRefPubMed
13.
Ohno Y, Noguchi M, Yokoi-Noguchi M, Nakano Y, Shimada K, Yamamoto Y, et al. Nipple- or skin sparing mastectomy by the moving window operation and immediate breast reconstruction. Breast Cancer. 2013;20:54–61.CrossRefPubMed
14.
Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, et al. AJCC cancer staging manual. 6th ed. New York: Springer; 2002. p. 223–40.CrossRef
15.
16.
Guller U, Nitzsche E, Moch H, Zuber M. Is positron emission tomography an accurate non-invasive alternative to sentinel lymph node biopsy in breast cancer patients? [commentary]. J Natl Cancer Inst. 2003;95:1040–3.CrossRefPubMed
17.
Veronesi U, De Cicco C, Galimberti VE, Fernandez JR, Rotmensz N, et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol. 2007;18:473–8.CrossRefPubMed
18.
Hodgson NC, Gulenchyn KY. Is there a role for positron emission tomography in breast cancer staging? J Clin Oncol. 2008;26:712–20.CrossRefPubMed
19.
Wahl RL, Siegel BA, Coleman RE, Gatsonis CG. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol. 2004;22:277–85.CrossRefPubMed
20.
Weir L, Worsley D, Bernstein V. The value of FDG positron emission tomography in the management of patients with breast cancer. Breast J. 2005;11:204–9.CrossRefPubMed
21.
Escalona S, Blasco JA, Reza MM, Andradas E, Gomez N. A systemic review of FDG-PET in breast cancer. Med Oncol. 2010;27:114–29.CrossRefPubMed
22.
Barranger E, Grahek D, Antoine M, Montravers F, Talbot JN, Uzan S. Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer. Ann Surg Oncol. 2003;10:622–7.CrossRefPubMed
23.
Heusner TA, Kuemmel S, Hahn S, Koeninger A, Otterbach F, Hamami ME, et al. Diagnostic value of full-dose FDG-PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging. 2009;36:1543–50.CrossRefPubMed
24.
Chung A, Liou D, Karlan S, Waxman A, Fujimoto K, Hagiike M, et al. Preoperative FDG-PET for axillary metastases in patients with breast cancer. Arch Surg. 2006;141:783–8.CrossRefPubMed
25.
Rousseau C, Bourbouloux E, Campion L, Fleury N, Bridji B, Chatal JF, et al. Brown fat in breast cancer patients: analysis of serial 18F-FDG PET/CT scans. Eur J Nucl Med Mol Imaging. 2006;33:785–91.CrossRefPubMed
26.
Krishnamurthy S. Current applications and future prospects of fine-needle aspiration biopsy of locoregional lymph nodes in the management of breast cancer. Cancer (Cancer Cytopathol). 2009;117:451–62.
27.
Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2011;252:426–33.
28.
Bonne BA, Huynh C, Spangler ML, Sumkin J, Johnson R, McGuire KP, et al. Axillary lymph node burden in invasive breast cancer: a comparison of the predictive value of ultrasound-guided needle biopsy and sentinel lymph node biopsy. Clin Breast Cancer. 2015;15(5):e243–8.CrossRef
29.
Cox K, Weeks J, Mills P, Chalmers R, Devalia H, Fish D, et al. Contrast-enhanced ultrasound biopsy of sentinel lymph nodes in patients with breast cancer: Implications for axillary metastases and conservation. Ann Surg Oncol. 2016;23:58–64.CrossRefPubMed
30.
Machida Y, Kubota K, Katayama T, Toriihara A, Shibuya H. Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography combined with ultrasonography-guided fine needle aspiration cytology for identifying axillary lymph node status in patients with breast cancer. Eur J Surg Oncol. 2013;39:26–30.CrossRefPubMed
31.
Dequanter D, Hertens D, Veys I, Nogaret JM, Larsimont D, Bourgeois P. Sentinel node involvement in T0-T1 breast cancers. Ann Chir. 2001;126:654–8.CrossRefPubMed
32.
Tanis PJ, Nieweg OE, Merkus JWS, Peterse JL, Kroon BBR. False negative sentinel nod procedure established through palpation of the biopsy wound. Eur J Surg Oncol. 2000;26:714–5.CrossRefPubMed
33.
Liberman L, Cody HS III. Percutaneous biopsy and sentinel lymphadenectomy: minimally invasive diagnosis and treatment of non-palpable breast cancer. AJR. 2001;177:887–91.CrossRefPubMed
34.
Boolbol SK, Fey JV, Borgen PI, Heerdt AS, Montgomery LL, Paglia M, et al. Intradermal isotope injection: a highly accurate method of lymphatic mapping in breast carcinoma. Ann Surg Oncol. 2001;8:20–4.CrossRefPubMed
35.
Crippa F, Gerali A, Alessi A, Agresti R, Bombardieri E. EDG-PET for axillary lymph node staging in primary breast cancer. Eur J Nucl Med Mol Imaging. 2004;31(Suppl. 1):S97–102.CrossRefPubMed
Metadata
Title
The roles of 18F-FDG-PET/CT and US-guided FNAC in assessment of axillary nodal metastases in breast cancer patients
Authors
Yasuharu Nakano
Masakuni Noguchi
Miki Yokoi-Noguchi
Yukako Ohno
Emi Morioka
Takeo Kosaka
Tomoko Takahashi
Hiroshi Minato
Publication date
01-01-2017
Publisher
Springer Japan
Published in
Breast Cancer / Issue 1/2017
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-016-0684-5

Other articles of this Issue 1/2017

Breast Cancer 1/2017 Go to the issue

Special Feature

Possible supplemental breast cancer screening modalities

Special Feature

Antitumor immunity and advances in cancer immunotherapy

Original Article

Efficacy and safety of re-induction therapy with bevacizumab and paclitaxel for metastatic breast cancer

Special Feature

Advances in personalized cancer immunotherapy

Original Article

Dietary patterns and breast cancer risk in a prospective Japanese study

Review Article

Melatonin, an inhibitory agent in breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits